Aarey Drugs & Pharmaceuticals share news, announcements and annual reports
NSE: AAREYDRUGSBSE: 524412Pharmaceuticals & BiotechnologySmall Cap
Aarey Drugs & Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Aug 2021 on NSE
Last close ₹106.26down ₹4.58 (4.13%)BSE ₹105.25
Share price at the NSE close on 30 Oct 2026. Previous close ₹110.84.
30 Oct: open ₹111.00, high ₹111.45, low ₹105.30
52-week range of traded prices to 30 Oct 2026
₹50.31Low, 30 Mar 2026₹114.80High, 19 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹339 Cr2,366th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.33
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 3,49,46176.1% delivered
Aarey Drugs & Pharmaceuticals disputes and clarifications
8 filed, newest first.
May 2026
Mar 2026
12 Mar · Legal
Exchange has sought clarification from Aarey Drugs & Pharmaceuticals Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.
Apr 2025
9 Apr · Legal
The exchange asked on 7 Apr 2025
Sep 2024
4 Sep · Legal
Exchange has sought clarification from Aarey Drugs & Pharmaceuticals Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Feb 2023
21 Feb · Legal
Exchange has sought clarification from Aarey Drugs & Pharmaceuticals Limited for the quarter ended 31-Dec-2022 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Sep 2022
7 Sep · Legal
Exchange has sought clarification from Aarey Drugs & Pharmaceuticals Limited with respect to Financial Results dated 13-Aug-2022 for the period Jun, 2022On the basis of aforesaid disclosure, the Listed entity is required to clarify the following:1. Segment Reporting- Not found.The response of the company is awaited